CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes

Journal of Clinical Investigation

Volumn 111, Issue 8, 2003, Pages 1133-1145

  Tiede, Imke ^a   Fritz, Gerhard ^a   Strand, Susanne ^a   Poppe, Daniela ^a   Dvorsky, Radovan ^b   Strand, Dennis ^a   Lehr, Hans Anton ^a   Wirtz, Stefan ^a   Becker, Christoph ^a   Atreya, Raja ^a   Mudter, Jonas ^a   Hildner, Kai ^a   Bartsch, Brigitte ^a   Holtmann, Martin ^a   Blumberg, Richard ^c   Walczak, Henning ^d   Iven, Heiko ^e   Galle, Peter R ^a   Ahmadian, Mohammad Reza ^b   Neurath, Markus F ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b MAX PLANCK INSTITUTE OF MOLECULAR PHYSIOLOGY   (Germany)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^e UNIVERSITY OF LÜBECK   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CD28 ANTIGEN; CD4 ANTIGEN; GUANOSINE TRIPHOSPHATE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOSUPPRESSIVE AGENT; MERCAPTOPURINE; PROTEIN BCL X; PROTEIN KINASE; RAC1 PROTEIN; TIOGUANINE;

ADULT; AGED; APOPTOSIS; ARTICLE; AUTOIMMUNE DISEASE; CHRONIC INFLAMMATION; CONTROLLED STUDY; CROHN DISEASE; DRUG MECHANISM; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG TARGETING; GENE TARGETING; HUMAN; HUMAN CELL; MITOCHONDRION; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; T LYMPHOCYTE;

EID: 0242464926     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI16432     Document Type: Article

References (62)

1. McGeown, M., et al. 1988. Ten-year results of renal transplantation with azathioprine and prednisolone as only immunosuppression. Lancet. 1:983-991.
2. Andreone, P.A., et al. 1986. Reduction of infectious complications following heart transplantation with triple-drug immunotherapy. J. Heart Transplant. 5:13-19.
3. British and Dutch Multiple Sclerosis Azathioprine Trial Group. 1988. Double-masked trial of azathioprine in multiple sclerosis. Lancet. 2:179-186.
4. DeSilva, M., and Hazleman, B.L. 1981. Long-term azathioprine in rheumatoid arthritis. A double-blind study. Ann. Rheum. Dis. 40:560-568.
5. Ginzler, E., Sharon, E., Diamond, H., and Kaplan, D. 1975. Long term maintenance therapy with azathioprine in systemic lupus erythematosus. Arthritis Rheum. 18:27-35.
6. Christensen, E., et al. 1985. Beneficial effect of azathioprine and prediction of prognosis in primary biliary cirrhosis. Final results of an international trial. Gastroenterology. 89:1084-1091.
7. Candy, S., et al. 1995. A controlled double blind study of azathioprine in the management of Crohn's disease. Gut. 37:674-678.
8. Bouhnik, Y., et al. 1996. Long-term follow-up of patients with Crohn's disease treated with azathioprine or 6-mercaptopurine. Lancet. 347:215-219.
9. D'Haens, G., Geboes, K., Ponette, E., Penninckx, F., and Rutgeerts, P. 1997. Healing of severe recurrent ileitis with azathioprine therapy in patients with Crohn's disease. Gastroenterology. 112:1475-1481.
10. Lewis, J.D., Schwartz, J.S., and Lichtenstein, G.R. 2000. Azathioprine for maintenance of remission in Crohn's disease: benefits outweigh the risk of lymphoma. Gastroenterology. 118:1018-1024.
11. Present, D.H., et al. 1980. Treatment of Crohn's disease with 6-mercaptopurine: a long-term randomized, double-blind study. N Engl. J. Med. 302:981-987.
12. Bean, R.H.D. 1962. The treatment of chronic active ulcerative colitis with 6-mercaptopurine. Med. J. Aust. 2:592-593.
13. Dimitriu, A., and Fauci, A.S. 1978. Activation of human B lymphocytes. XI. Differential effects of azathioprine on B lymphocytes and lymphocyte subpopulations regulating B cell function. J. Immunol. 121:2335-2339.
14. Lennard, L. 1992. The clinical pharmacology of 6-mercaptopurine. Eur. J. Clin. Pharmacol. 43:329-335.
15. Röllinghoff, M., Schrader, J., and Wagner, H. 1973. Effect of azathioprine and cytosine arabinoside on humoral and cellular immunity in vitro. Clin. Exp. Immunol. 15:261-269.
16. Abdou, N.I., Zweiman, B., and Casella, S.R. 1973. Effects of azathioprine therapy on bone marrow-dependent and thymus-dependent cells in man. Clin. Exp. Immunol. 13:55-64.
17. Bach, M.A., and Bach,J.F. 1972. Activities of immunosuppressive agents in vitro. II. Different timing of azathioprine and methotrexate in inhibition and stimulation of mixed lymphocyte reaction. Clin. Exp. Immunol. 11:89-98.
18. Hoffmann, M., Rychlewski, J., Chrzanowska, M., and Hermann, T. 2001. Mechanism of activation of an immunosuppressive drug: azathioprine. Quantum chemical study on the reaction of azathioprine with cysteine. J. Am. Chem. Soc. 123:6404-6409.
19. Kroplin, T., and Iven, H. 2000. Methylation of 6-mercaptopurine and 6-thioguanine by thiopurine S-methyltransferase. A comparison of activity in red blood cell samples of 199 blood donors. Eur. J. Clin. Pharmacol. 56:343-345.
20. Van Os, E.C., et al. 1996. Azathioprine pharmacokinetics after intravenous, oral, delaved release oral and rectal foam administration. Gut. 39:63-68.
21. Podolsky, D.K. 1991. Inflammatory bowel disease. N. Engl. J. Med. 325:928-937.
22. Beutler, B. 2001. Autoimmunity and apoptosis: the Crohn's connection. Immunity. 15:5-14.
23. Neurath, M.F., Finotto, S., and Glimcher, L.H. 2002. The role of Th1/Th2 polarization in mucosal immunity. Nat. Med. 8:567-573.
24. MacDonald, T.T., Monteleone, G., and Pender, S.L.F. 2000. Recent developments in the immunology of inflammatory bowel disease. Scand. J. Immunol. 51:2-9.
25. Shanahan, F. 2002. Crohn's disease. Lancet. 359:62-69.
26. Hugot, J.P., et al. 2001. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature. 411:599-603.
27. Ogura, Y., et al. 2001. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 411:603-606.
28. Targan, S.R., et al. 1997. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. N. Engl. J. Med. 337:1029-1035.
29. Elson, C.O., Sartor, R.B., Tennyson, G.S., and Riddell, R.H. 1995. Experimental models of inflammatory bowel disease. Gastroenterology. 109:1344-1367.
30. Atreya, R., et al. 2000. Blockade of IL-6 trans-signaling suppresses T cell resistance against apoptosis in chronic intestinal inflammation: evidence in Crohn's disease and experimental colitis in vivo. Nat. Med. 6:583-588.
31. Breese, E., Braegger, C.P., Corrigan, C.J., Walker-Smith, J.A., and MacDonald, T.T. 1993. Interleukin-2 and interferon-gamma secreting T cells in normal and diseased human intestinal mucosa. Immunology. 78:127-131.
32. Plevy, S.E., et al. 1997. A role for TNF-alpha and mucosal T helper-1 cytokines in the pathogenesis of Crohn's disease. J. Immunol. 159:6276-6282.
33. Boirivant, M., et al. 1999. Lamina propria T cells in Crohn's disease and other gastrointestinal inflammation show defective CD2 pathway-induced apoptosis. Gastroenterology. 116:557-565.
34. Sandborn, W.J., et al. 1999. Lack of effect of intravenous administration on time to respond to azathioprine for steroid-treated Crohn's disease. Gastroenterology. 117:527-535.
35. Pearson, D.C., May, G.R., Fick, G.H., and Sutherland, L.R. 1995. Azathioprine and 6-mercaptopurine in Crohn disease. A meta-analysis. Ann. Intern. Med. 123:132-142.
36. Ewe, K., et al. 1993. Azathioprine combined with prednisolone or monotherapy with prednisone in active Crohn's disease. Gastroenterology. 105:367-376.
37. Holtmann, M.H., et al. 2002. Tumor necrosis factor-receptor 2 is upregulated on lamina propria T cells in Crohn's disease and promotes experimental colitis in vivo. Eur. J. Immunol. 32:3142-3151.
38. Noel, P.J., Boise, L.H., Green, J.M., and Thompson, C.B. CD28 co-stimulation prevents cell death during primary T cell activation. J. Immunol. 157:636-647.
39. Radvanyi, L.G., et al. 1996. CD28 costimulation inhibits TCR-induced apoptosis during a primary T cell response. J. Immunol. 156:1788-1798.
40. + lymphocytes. J. Immunol. 165:1743-1754.
41. Jodo, S., et al. 2000. CD95 (Fas) ligand-expressing vesicles display antibodymediated, FcR-dependent enhancement of cytotoxicity. J. Immunol. 165:5487-5494.
42. Nicoletti, I., Migliorati, G., Pagliacci, M.C., Grignani, F., and Riccardi, C. 1991. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J. Immunol. Methods. 139:271-279.
43. Finotto, S., et al. 2001. Treatment of allergic airway inflammation and hyperresponsiveness by local antisense-induced blockade of GATA·3 expression. J. Exp. Med. 193:1247-1260.
44. Scaffidi, C., Kirchhoff, S., Krammer, P.H., and Peter, M.E. 1999. Apoptosis signaling in lymphocytes. Curr. Opin. Immunol. 11:277-285.
45. Neurath, M.F., et al. 2001. Regulation of T-cell apoptosis in inflammatory bowel disease: to die or not to die, that is the mucosal question. Trends Immunol. 22:21-26.
46. Cuffari, C., Seidman, E.G., Latour, S., and Theoret, Y. 1996. Quantification of 6-thioguanine in peripheral blood leukocyte DNA in Crohn's disease patients on maintenance 6-mercaptopurine therapy. Can. J. Physiol. Pharmacol. 74:580-585.
47. Zamzami, N., et al. 1995. Reduction in mitochondrial potential constitutes an early irreversible step of programmed lymphocyte death in vivo. J. Exp. Med. 181:1661-1672.
48. Kirchhoff, S., Müller, W.W., Li-Weber, M., and Krammer, P.H. 2000. Up-regulation of c-FLIPshort and reduction of activation-induced cell death in CD28-co-stimulated human T cells. Eur. J. Immunol. 30:2765-2774.
49. Tuosto, L., et al. 2000. Mitogen-activated kinase kinase kinase 1 regulates T cell receptor and CD28-mediated signaling events which lead to NF-κB activation. Eur. J. Immunol. 30:2445-2454.
50. Chiang, Y.J., et al. 2000. Cbl-b regulates the CD28 dependence of T-cell activation. Nature. 403:216-220.
51. Krawczyk, C., et al. 2000. Cbl-b is a negative regulator of receptor clustering and raft aggregation in T cells. Immunity. 13:463-473.
52. Raab, M., Pfister, S., and Rudd, C.E. 2001. CD28 signaling via VAV/SLP-76 adaptors: regulation of cytokine transcription independent of TCR ligation. Immunity. 15:921-933.
53. Simon, A.R., et al. 2000. Regulation of STAT3 by direct binding of the Rac1 GTPase. Science. 290:144-147.
54. Lenardo, M., et al. 1999. Mature T lymphocyte apoptosis - immune regulation in a dynamic and unpredictable antigenic environment. Annu. Rev. Immunol. 17:221-253.
55. Boise, L.H., Noel, P.J., and Thompson, C.B. 1995. CD28 and apoptosis. Curr. Opin. Immunol. 7:620-625.
56. + helper T cells. A model for the long-term survival of memory cells. J. Immunol. 156:1764-1771.
57. Marinan, B., et al. 2002. Vav cooperates with CD28 to induce NF-κB activation via a pathway involving Rac-1 and mitogen-activated kinase kinase 1. Eur. J. Immunol. 32:447-456.
58. Gomez, M., Tybulewicz, V., and Cantrell, D.A. 2000. Control of pre T cell proliferation and differentiation by the GTPase Rac1. Nat. Immunol. 1:348-352.
59. Joneson T., and Bar-Sagi, D. 1999. Suppression of Ras-induced apoptosis by the Rac GTPase. Mol. Cell. Biol. 19:5892-5901.
60. Li, B., et al. 2000. Role of the guanosine triphosphate Rac2 in T helper 1 cell differentiation. Science. 288:2219-2222.
61. Williams, D.A., et al. 2000. Dominant negative mutation of the hematopoietic-specific Rho GTPase, Rac2, is associated with a human phagocyte immunodeficiency. Blood 96:1646-1654.
62. Kaga, S., Ragg, S., Rogers, K.A., and Ochi, A. 1998. Activation of p21-CDC42/Rac-activated kinases by CD28 signaling: p21-activated kinase (PAK) and MEK kinase I (MEKK1) may mediate the interplay between CD3 and CD28 signals. J. Immunol. 160:4182-4189.